AN ACT TO AUTHORIZE PHARMACISTS TO DISPENSE ALBENDAZOLE AND MEBENDAZOLE WITHOUT REQUIRING A PRESCRIPTION FROM A LICENSED HEALTH CARE PRACTITIONER; TO PROVIDE IMMUNITY FOR PHARMACISTS DISPENSING ALBENDAZOLE AND MEBENDAZOLE IN A REASONABLY PRUDENT MANNER IN ACCORDANCE WITH THIS ACT; AND FOR RELATED PURPOSES.
Summary
House Bill 529 would allow Mississippi pharmacists to dispense albendazole and mebendazole without first obtaining a prescription from a licensed health care practitioner. The bill directs pharmacists to follow any standardized procedures or protocols adopted by the State Board of Pharmacy, and it allows those protocols to include patient instructions on proper use of the medications.
The measure also creates liability protection for pharmacists who dispense either drug in a reasonably prudent manner and in compliance with the act. It authorizes the State Board of Pharmacy to adopt rules needed to implement the new authority, and the bill would take effect July 1, 2026.
Impact
HB529 would amend Mississippi law to create a pharmacist-access pathway for two antiparasitic medications, albendazole and mebendazole, without a traditional prescription requirement. It shifts some dispensing authority from prescribers to pharmacists, while leaving the State Board of Pharmacy responsible for establishing any operational standards, protocols, and implementation rules. The bill also limits criminal, civil, and professional disciplinary exposure for pharmacists acting prudently under the new framework.
Sentiment
No committee transcript or vote record was provided, so there is no direct evidence of debate, support, or opposition in the available materials. Based on the text alone, the bill appears narrowly targeted and administrative in nature, focused on expanding access and reducing barriers to obtaining these medications. The absence of recorded discussion makes the overall sentiment difficult to assess beyond the bill’s straightforward policy design.
Contention
The main potential point of contention is the shift away from a prescription requirement, which may raise concerns about pharmacist scope of practice, patient safety, and appropriate oversight. Supporters would likely emphasize improved access, convenience, and faster treatment for parasitic infections, while critics may question whether dispensing without a prescriber evaluation is sufficiently controlled. Any disagreement would likely center on the details of the Board of Pharmacy protocols and the extent of immunity granted to pharmacists.